Imperial College London

ProfessorDavidSharp

Faculty of MedicineDepartment of Brain Sciences

Professor of Neurology
 
 
 
//

Contact

 

+44 (0)20 7594 7991david.sharp Website

 
 
//

Location

 

UREN.927Sir Michael Uren HubWhite City Campus

//

Summary

 

Summary

Professor David Sharp is a neurologist and Centre Director of UK DRI Care Research & Technology, focusing on using technology to enhance the lives of people living with dementia. He is also Scientific Director of the Imperial College Clinical Imaging Facility and Associate Director of the Imperial Centre for Injury Studies. His research programme aims to improve clinical outcomes after dementia and traumatic brain injury (TBI), focusing on common cognitive impairments in domains such as memory and attention. He uses cognitive neuroscience and advanced neuroimaging to investigate the effect of brain injury on brain network function and the effects of inflammation and neurodegeneration. His has explored how new treatments of cognitive impairment can be personalised and his current work focuses on harnessing neurotechnology development to improve the lives of those living with dementia and the effects of brain injury.

Publications

Journals

Fang Z, Chen R, Fröch JE, et al., 2024, Nonvolatile Phase-Only Transmissive Spatial Light Modulator with Electrical Addressability of Individual Pixels., Acs Nano, Vol:18, Pages:11245-11256

Lai H, Kolanko M, Li LM, et al., 2024, Population incidence and associated mortality of urinary tract infection in people living with dementia., J Infect, Vol:88

Zimmerman KA, Hain JA, Graham NSN, et al., 2024, Prospective cohort study of long-term neurological outcomes in retired elite athletes: the Advanced BiomaRker, Advanced Imaging and Neurocognitive (BRAIN) Health Study protocol., Bmj Open, Vol:14

Kirby P, Lai H, Horrocks S, et al., 2024, Patient and public involvement in technology-related dementia research: a scoping review, Jmir Aging, Vol:7, ISSN:2561-7605

Graham N, Zimmerman K, Heslegrave A, et al., 2024, Alzheimer’s disease marker phospho-tau181 is not elevated in the first year after moderate-severe TBI, Journal of Neurology, Neurosurgery and Psychiatry, Vol:95, ISSN:0022-3050, Pages:356-359

More Publications